Healthcare stocks underperformed the market last year, but there are a few companies that look like solid long-term holds right now according to a recent analysis. **Eli Lilly (LLY)** They hit a $1 trillion valuation recently, driven largely by their weight-loss drugs like tirzepatide. They have an oral version expected for approval this year and are investing heavily in AI to speed up drug development. **AbbVie (ABBV)** Growth is coming from Skyrizi and Rinvoq now that the Humira patent has expired. The company has a diverse lineup including Botox and is a Dividend King, meaning they have raised payouts for 50+ years straight. **Intuitive Surgical (ISRG)** They dominate robotic surgery with the da Vinci system. The moat here is strong because hospitals invest a lot in the equipment and training, making switching costs high. An aging population should keep procedure volume up.